Related Experiment Video
Updated: Aug 11, 2026
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
[Outcome of Eight-Year-Experiences of BCG Intravesical Instillation Therapy in Patients with Non-Muscle Invasive
Junichi Hori1, Masayuki Tokumitsu, Satoshi Yamaguchi
1Dept. of Urology, Kitasaito Hospital.
We retrospectively investigated the outcome of BCG intravesical instillation therapy for patients with non-muscle invasive bladder cancer. From 2011 to 2019, a total of 79 patients had received BCG intravesical instillation therapy for non-muscle invasive bladder cancer. Of these 79 patients, 62 were included in this study. The protocol of BCG intravesical instillation therapy was as follows: instillation once per week for 6 consecutive weeks as induction, followed by instillation twice (once per week for 2 consecutive weeks) at each of 4, 6 and 12 months after TUR-BT as maintenance. BCG completion rate was 42%. The most frequent reasons for BCG discontinuation were adverse events of BCG treatment (70%). Two-year bladder non-recurrence survival was 72%. BCG completion group showed a statistically significant better bladder non-recurrence survival compared to BCG non-completion group. However, when we focused on the patients who discontinued BCG treatment only due to adverse events, bladder non-recurrence survival in this patient group was not different from BCG completion group. In conclusion, adverse events resulting in discontinuation of BCG treatment seem to be a prognostic factor for the efficacy of BCG treatment. But from the perspective of patient's quality of life, a better management is required to prevent adverse events of BCG treatment and to promote the BCG completion rate.
We retrospectively investigated the outcome of BCG intravesical instillation therapy for patients with non-muscle invasive bladder cancer. From 2011 to 2019, a total of 79 patients had received BCG intravesical instillation therapy for non-muscle invasive bladder cancer. Of these 79 patients, 62 were included in this study. The protocol of BCG intravesical instillation therapy was as follows: instillation once per week for 6 consecutive weeks as induction, followed by instillation twice (once per week for 2 consecutive weeks) at each of 4, 6 and 12 months after TUR-BT as maintenance. BCG completion rate was 42%. The most frequent reasons for BCG discontinuation were adverse events of BCG treatment (70%). Two-year bladder non-recurrence survival was 72%. BCG completion group showed a statistically significant better bladder non-recurrence survival compared to BCG non-completion group. However, when we focused on the patients who discontinued BCG treatment only due to adverse events, bladder non-recurrence survival in this patient group was not different from BCG completion group. In conclusion, adverse events resulting in discontinuation of BCG treatment seem to be a prognostic factor for the efficacy of BCG treatment. But from the perspective of patient's quality of life, a better management is required to prevent adverse events of BCG treatment and to promote the BCG completion rate.